Our results indicate that SLC44A2 acts as a tumor suppressor in CRC by downregulating CPT2-mediated mitochondrial fatty acid oxidation via increasing the interaction between MUL1 and CPT2, supporting SLC44A2 as a potential therapeutic target in the treatment of this malignancy. The gene discussed is SLC44A2; the disease is colorectal carcinoma.